Vis enkel innførsel

dc.contributor.authorSerigstad, S.
dc.contributor.authorGrewal, Harleen
dc.contributor.authorEbbesen, Marit Helen
dc.contributor.authorKommedal, Øyvind
dc.contributor.authorHeggelund, Lars
dc.contributor.authorvan Werkhoven, Werkhoven
dc.contributor.authorFaurholt-Jepsen, D.
dc.contributor.authorClark, T.W.
dc.contributor.authorRitz, Christian
dc.contributor.authorUlvestad, Elling
dc.contributor.authorBjørneklett, Rune Oskar
dc.contributor.authorKnoop, S.T.
dc.contributor.authorRavn, P.
dc.contributor.authorMarkussen, Dagfinn Lunde
dc.date.accessioned2022-06-01T12:22:16Z
dc.date.available2022-06-01T12:22:16Z
dc.date.created2022-05-10T15:36:55Z
dc.date.issued2022
dc.identifier.issn2045-2322
dc.identifier.urihttps://hdl.handle.net/11250/2997239
dc.description.abstractLack of rapid and comprehensive microbiological diagnosis in patients with community acquired pneumonia (CAP) hampers appropriate antimicrobial therapy. This study evaluates the real-world performance of the BioFire FilmArray Pneumonia panel plus (FAP plus) and explores the feasibility of evaluation in a randomised controlled trial. Patients presenting to hospital with suspected CAP were recruited in a prospective feasibility study. An induced sputum or an endotracheal aspirate was obtained from all participants. The FAP plus turnaround time (TAT) and microbiological yield were compared with standard diagnostic methods (SDs). 96/104 (92%) enrolled patients had a respiratory tract infection (RTI); 72 CAP and 24 other RTIs. Median TAT was shorter for the FAP plus, compared with in-house PCR (2.6 vs 24.1 h, p < 0.001) and sputum cultures (2.6 vs 57.5 h, p < 0.001). The total microbiological yield by the FAP plus was higher compared to SDs (91% (162/179) vs 55% (99/179), p < 0.0001). Haemophilus influenzae, Streptococcus pneumoniae and influenza A virus were the most frequent pathogens. In conclusion, molecular panel testing in adults with CAP was associated with a significant reduction in time to actionable results and increased microbiological yield. The impact on antibiotic use and patient outcome should be assessed in randomised controlled trials.en_US
dc.language.isoengen_US
dc.publisherNature Researchen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleRapid syndromic PCR testing in patients with respiratory tract infections reduces time to results and improves microbial yielden_US
dc.title.alternativeRapid syndromic PCR testing in patients with respiratory tract infections reduces time to results and improves microbial yielden_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright The Author(s) 2022en_US
dc.source.articlenumber326en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1038/s41598-021-03741-7
dc.identifier.cristin2023199
dc.source.journalScientific Reportsen_US
dc.identifier.citationScientific Reports. 2022, 12, 326.en_US
dc.source.volume12en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal